https://www.technologynetworks.com/drug-discovery/news/ym-biosciences-reports-phase-iii-data-for-jak-inhibitor-cyt387-at-ash-2012-214388
68% transfusion independence response rate and 37% durable spleen response rate.
ym biosciencesjak inhibitorreportsphaseii